Cocrystal Pharma (OTCMKTS:COCP) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Cocrystal Pharma (OTCMKTS:COCP) in a research note released on Wednesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $5.00 price target on the stock.

Separately, Noble Financial began coverage on Cocrystal Pharma in a research report on Tuesday, June 16th. They set an outperform rating and a $5.00 target price on the stock.

Shares of Cocrystal Pharma stock opened at $1.83 on Wednesday. The firm’s 50-day moving average is $1.26 and its 200 day moving average is $0.90. Cocrystal Pharma has a 1 year low of $0.39 and a 1 year high of $2.95.

Cocrystal Pharma (OTCMKTS:COCP) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $0.46 million during the quarter.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COCP. Parallel Advisors LLC raised its stake in Cocrystal Pharma by 161.6% during the first quarter. Parallel Advisors LLC now owns 128,563 shares of the company’s stock valued at $91,000 after buying an additional 79,419 shares in the last quarter. Renaissance Technologies LLC boosted its position in Cocrystal Pharma by 1,128.8% in the fourth quarter. Renaissance Technologies LLC now owns 129,274 shares of the company’s stock valued at $64,000 after buying an additional 118,754 shares in the last quarter. Royal Bank of Canada boosted its position in Cocrystal Pharma by 140,351.2% in the first quarter. Royal Bank of Canada now owns 178,373 shares of the company’s stock valued at $126,000 after buying an additional 178,246 shares in the last quarter. Acadian Asset Management LLC boosted its position in Cocrystal Pharma by 1,354.9% in the first quarter. Acadian Asset Management LLC now owns 187,425 shares of the company’s stock valued at $133,000 after buying an additional 174,543 shares in the last quarter. Finally, Sabby Management LLC acquired a new position in Cocrystal Pharma in the first quarter valued at about $278,000.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

See Also: Quiet Period Expirations

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.